help button home button Endocrine Society Molecular Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on June 26, 2007
Molecular Endocrinology, doi:10.1210/me.2007-0143
A more recent version of this article appeared on October 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
21/10/2403    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Failor, K. L.
Right arrow Articles by Firestone, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Failor, K. L.
Right arrow Articles by Firestone, G. L.

Submitted on March 15, 2007
Accepted on June 18, 2007

Glucocorticoid-induced degradation of GSK3 protein is triggered by Sgk and Akt signaling and controls beta-catenin dynamics and tight junction formation in mammary epithelial tumor cells

Kim L. Failor, Yelena Desyatnikov, Lindsay A. Finger, and Gary L. Firestone*

Department of Molecular and Cell Biology and The Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720-3200

* To whom correspondence should be addressed. E-mail: glfire{at}berkeley.edu.

Glucocorticoid hormones stimulate adherens junction and tight junction formation in Con8 mammary epithelial tumor cells and induce the production of a stable nonphosphorylated beta-catenin protein localized exclusively to the cell periphery. Glycogen Synthase Kinase-3 (GSK3) phosphorylation of beta-catenin is known to trigger the degradation of this adherens junction protein suggesting that steroid activated cascades may be targeting this protein kinase. We now demonstrate that treatment with the synthetic glucocorticoid dexamethasone induces the ubiquitin-26S proteasome mediated degradation of GSK3 protein with no change in GSK3 transcript levels. In transfected cells, deletion of the N-terminal nine amino acids or mutation of the serine-9 phosphorylation site on GSK3-beta prevented its glucocorticoid induced degradation. Expression of stabilized GSK3 mutant proteins ablated the glucocorticoid induced tight junction sealing and resulted in production of a nonphosphorylated beta-catenin that localizes to both the nucleus and the cell periphery in steroid treated cells. Serine-9 on GSK3 can be phosphorylated by Sgk (serum- and glucocorticoid- induced protein kinase) and by Akt. Expression of dominant negative forms of either Sgk or Akt inhibited glucocorticoid induced GSK3 ubiquitination and degradation, and disrupted the dexamethasone induced effects on beta-catenin dynamics. Furthermore, the steroid induced tight junction sealing is attenuated in cells expressing dominant negative forms of either Sgk or Akt, although the effect of blunting Sgk signaling was significantly greater. Taken together, we have uncovered a new cellular cascade in which Sgk and Akt trigger the glucocorticoid regulated phosphorylation, ubiquitination and degradation of GSK3, which alters beta-catenin dynamics, leading to the formation of adherens junctions and tight junction sealing.


Key words: Glucocorticoids • adherens junction • tight junction • GSK3 • Akt • Sgk

NURSA Molecule Pages Link:

Ligands:   Dexamethasone






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society